This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

'Fast Money' Recap: A Down Day

NEW YORK (TheStreet) -- The Nasdaq led U.S. equities lower on Friday, closing down by nearly 1%. 

On CNBC's "Fast Money" TV show, Brian Kelly, founder of Brian Kelly Capital, said investors are rotating out of high-growth stocks and into stocks like Microsoft (MSFT), Cisco Systems (CSCO) and U.S. Steel (X).

Pete Najarian, co-founder of optionmonster.com and trademonster.com, said many financial stocks hit 52-week highs on Friday -- including Bank of America (BAC), Wells Fargo (WFC) and JPMorgan Chase (JPM) -- before pulling back and ending the session lower. He attributed the selloff to profit taking and remained bullish. He bought Goldman Sachs (GS).

Steve Grasso, director of institutional sales at Stuart Frankel, said a lot of the selloffs on Friday were exacerbated. He was also a buyer of financial stocks on this pullback. 

Guy Adami, managing director of stockmonster.com, pointed out the weakness in the biotech sector, with the iShares Nasdaq Biotechnology ETF (IBB) selling off 4.75%. Specifically, he suggested that investors wait for Celgene (CELG) to consolidate before stepping in to buy. 

Biogen Idec (BIIB) was among the biotech stocks that got hit on Friday, falling over 8%. George Scangos, CEO of Biogen, said the company's hemophilia A and hemophilia B drugs should do very well and are currently available in Germany and Norway. He added the drugs will spread throughout the rest of Europe when the negotiated price is finalized with the other countries. He agreed with estimates that the drugs could grow into a $7 billion market for the company. 

Adami said Biogen has a strong pipeline of drugs and is not expensive, trading at 22 times forward earnings. However, like Celgene, he suggested investors let the stock settle down for several trading sessions before buying. 

Kelly said he preferred to play biotech stocks through an exchange-traded fund because of its diversity and his lack of knowledge in the specific companies. 

Najarian disagreed with the biotech ETF approach, saying investors should deeply research specific companies to find the good ones. He agreed with Adami that Biogen has a strong pipeline and a low valuation. 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs